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Objective: To evaluate the therapeutic effects and safety of the XIA’s No.1 Sleeping Prescription for the 
treatment of insomnia of the deficiency type. Methods: 120 cases conformed to the diagnostic criteria of the 
Chinese Classification of Mental Disorders-Version 3 (CCMD-3) and were diagnosed as having insomnia of 
the deficiency type were divided randomly into a treatment group and a control group, 60 cases in each group. 
The treatment group was treated with the XIA’s No.1 Sleeping Prescription, while the control group was 
given estazolam (1mg) for 6 weeks. The Athens Insomnia Scale (AIS) was used to evaluate the clinical 
therapeutic effects, while the treatment emergent symptom scale (TESS) was used to evaluate adverse 
reactions. Results: The total effective rate of the treatment group (80%) was higher than that of the control 
group (70%), but with no significant difference (P>0.05). The effective rate for long-term insomnia was 
77.8% in the treatment group and 52.4% in the control group, with a significant difference between the two 
groups (P<0.05). The adverse reactions shown in the treatment group were obviously fewer and milder than 
those in the control group. Conclusion: The XIA’s No. 1 Sleeping Prescription is effective for insomnia of 
the deficiency type and with no obvious toxic side effects.  
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Commonly used sleeping pills have definite sedative 
and hypnotic effects, yet they can bring about such 
symptoms as day-time lethargy, dizziness, asthenia, 
forgetfulness, restricted thought, and ataxia. They 
also present problems to patients with varying 
degrees of such as liver and kidney damage, chronic 
obstructive lung diseases, myasthenia gravis, and 
glaucoma, and should can cause potential problems 
for pregnant and breast-feeding women. Large-dose 
and long-term administration of such drugs can make 
the patient develop drug resistance and addiction; and 
a sudden drop of the drug or medication with 
decreased dosage can make the patient have the 
drug-withdrawal symptoms of anxiety or depression.1
Based on the traditional TCM theory and long years 
of clinical application, the authors have developed a 
prescription for insomnia of the deficiency type, the 
XIA’s No.1. Sleeping Prescription. For further 
research confirming the therapeutic effects and safety 
of this prescription, they conducted clinical 
observations from December 2003 to December 2005, 
with estazolam taken as the control drug, to provide 
the evidence for clinical treatment of insomnia. A 
report follows. 
CLINICAL MATERIALS 
The Study Inclusion Criteria 
All 120 cases were outpatients from the special 
department for insomnia of Lishui Second Municipal 
People’s Hospital. The study inclusion criteria: The 
patients conformed to the diagnostic criteria of 
insomnia set in Chinese Classification of Mental 
Disorders-Version 3 (CCMD-3), 2 and differentiated 
by TCM as insomnia of the deficiency type: 1) 
difficulty in falling asleep (>30 minutes); 2) 
dreaminess, waking up during sleep (>2 times), early 
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waking up, and inability to fall asleep again after 
waking up; 3) total sleeping time less than 5 hours 
each night; 4) the accompanying symptoms: 
palpitation, shortness of breath, vexation, lassitude, 
asthenia, forgetfulness, mental restlessness, dizziness 
and tinnitus, dry throat and thirst, spontaneous and 
night sweating, soreness and weakness of the waist 
and knee joints, feverish sensations in the palms and 
soles, loss of taste, dull complexion,  spermato- 
rrhoea and impotence in men or irregular mens- 
truations in women; and 5) pale tongue with thin 
coating or red tongue with little coating, and 
thready-weak or thready-rapid pulse.3  
The Exclusion Criteria  
1) Insomnia due to organic diseases of the body or 
brain; 2) insomnia due to mental disorders; 3) 
insomnia due to alcohol, coffee, tea, or drug 
dependence; and 4) patients with severe suicidal 
behaviors.  
General Data 
The 120 cases conformed to the above criteria were 
divided randomly into two groups. In the treatment 
group of 60 cases, 15 were male and 45 female, 
ranging in age from 24–61 years (mean 42.18±9.82 
years), with duration of illness 11.09±14.27 months; 
42 cases had short-term insomnia (1–6 months), and 
18 cases long-term insomnia (>6 months). In the 
control group of 60 cases, 18 were male and 42 
female, ranging in age from 24–62 years (mean 
42.75±10.72 years), the duration of illness 
11.84±14.29 months; 39 cases had short-term 
insomnia, and 21 cases long-term insomnia. There 
were no significant statistical difference between the 
two groups in the above items, and in the 
pretreatment AIS score, and the severity of the 
condition (P>0.05). 
METHODS 
Administration 
Before treatment, all the patients underwent a 
drug-clearing period for one week. Then, the 
treatment group was given the XIA’s No.1 Sleeping 
Prescription, consisting of Huang Qi (咘㡾 Radix 
Astragali) 30g, Bai Zhu (ⱑᴃ Rhizoma Atractylodis 
Macrocephalae) 5g, Suan Zao Ren (䝌ᵷҕ Semen 
Ziziphi Spinosae) 15g, Ye Jiao Teng (໰Ѹ㮸 Caulis 
Polygoni Multiflori) 30g, He Huan Pi (ড়⃶Ⲃ Cortex 
Albiziae) 15g, Dan Shen (Ѝখ Radix Salviae 
Miltiorrhizae) 20g, Huai Xiao Mai (⏂ᇣ呺) 30g, Fu 
Ling (㤃㢧 Poria) 15g, Zhi Yuan Zhi (♭䖰ᖫ Radix 
Polygalae Preparata) 15g, Long Gu (啭偼 Os 
Draconis Fossilia Ossis) 20g, and E Jiao (䰓㛊 Colla 
Corii Asini) 10g, which were made into decoction to 
be taken orally one dose daily in twice. The control 
group was given estazolam tablets (produced by 
Xinchang Pharmaceutical Factory of Zhejiang 
Medical Corporation, Ltd) 1mg taken daily  before 
bedtime. The two groups were treated for 6 weeks. 
Observation Indexes 
Evaluations by the Athens Insomnia Scale (AIS), on 
the severity of insomnia condition, and by the 
Treatment Emergent Symptom Scale (TESS) were 
done for the two groups respectively before the 
treatment and at the end of the 1st, 2nd, 4th, and 6th 
week. During the treatment course, adverse reactions 
were observed. Blood biochemical tests were made 
once respectively before and after the treatment, 
including alanine transaminase, aspartate trans- 
aminase, urea nitrogen, creatinine, and fasting blood- 
glucose. Electrolyte and EEG were conducted once 
respectively before and after the treatment. At the end 
of each week, routine blood examinations 
(hemoglobin, red blood cells, white blood cells and 
platelet count), routine urine examinations (glucose 
in urine, urinary protein, urinary white blood cells 
and red blood cells), and ECG were given. The blood 
pressure and pulse were examined every day. The 
Kappa value of uniformity test for the researchers 
involved was 0.87 (P>0.05).  
Statistical Methods 
All data underwent SPSS11.5 statistical analysis. The 
t test and Ȥ2 test were used for comparisons of the 
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general data. Radit analysis was used for comparison 
of the clinical therapeutic effects. Wilcoxon test was 
used for the AIS and TESS scorings. The Ȥ2 test was 
used for comparison of the occurrence rate of adverse 
reactions.  
RESULTS 
Criteria for the Therapeutic Effects 
Grading of insomnia: 1) Mild: occasional insomnia, 
which slightly affected the life quality; 2) Moderate: 
insomnia occurring every night, which moderately 
affected the life quality and was accompanied with 
such symptoms as peevishness, anxiety and lassitude; 
3) Severe: insomnia occurring every night, which 
seriously affected the life quality and was 
accompanied with marked clinical symptoms.  
The reducing rate of AIS score = ((basic AIS total 
score – post treatment total AIS score) ÷ basic AIS 
total score) × 100%. Clinically cured: the AIS score 
reducing rate was 90%. Markedly Relieved: the AIS 
score reducing rate was 60%–89%. Improved: the 
AIS score reducing rate was 30%–59%. Failed: the 
AIS score reducing rate was <30%.  
The adverse reaction: Those with the following 
conditions were determined to have adverse reactions: 
1) The relation between symptom and drug was 
evaluated as positive by using the TESS Scale; and 2) 
the TESS score was 2. The occurrence rate of the 
adverse reactions = the number of cases with adverse 
reactions/total number of cases × 100%.  
Comparison of the Therapeutic Effects (see Table 
1) 
Table 1 shows that after the 6-week treatment, the 
total effective rate was 80% in the treatment group, 
and 70% in the control group, with no significant 
difference between the two groups (P>0.05). For 
treatment of short-term insomnia, the total effective 
rate was 80.95% in the treatment group, which was 
slightly higher than that of the control group 
(79.49%), with no significant difference (P>0.05). 
For treatment of long-term insomnia, the total 
effective rate was 77.78% in the treatment group, 
which was obviously higher than the 52.38% of the 
control group, and the Ridit analysis showed a 
significant difference (P<0.05).  
Table 1. Comparison of the Therapeutic Effects (Cases (%)) 
Group n Cured Markedly Relieved Improved Failed Total Effectiveness
Treatment 60 13(21.67) 20(33.33) 15(25.00) 12(20.00) 48(80.00) 
Short-term 42 9(21.43) 15(35.71) 10(23.81) 8(19.05) 34(80.95) 
Long-term 18 4(22.22) 5(27.78) 5(27.78) 4(22.22) 14(77.78)*
Control 60 10(16.67) 15(25.00) 17(28.33) 18(30.00) 42(70.00) 
Short-term 39 9(23.08) 12(30.77) 10(25.64) 8(20.51) 31(79.49) 
Long-term 21 1(4.76) 3(14.29) 7(33.33) 10(47.62) 11(52.38) 
Notes: The intergroup comparison, *P<0.05  
Comparison of the AIS Scores (see Table 2) 
From the end of the first week, the AIS scores of the 
two groups showed significant differences compared 
to those before the treatment (P<0.01). The 
intergroup comparison of the AIS scores (including 
the short-term and long-term AIS scores) at the end 
of the 2nd and 4th week showed significant 
differences (P<0.01, or P<0.05), while the scores at 
the end of the 1st and 6th week didn’t show 
significant differences (P>0.05), suggesting that the 
therapeutic effects of the XIA’s prescription and 
estazolam are basically equal.  
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Table 2. Comparison of the AIS Score Before and After Treatment ( x fs)
Group n Before 
treatment 
End of 1st 
week 
End of 2nd 
week 
End of 4th 
week 
End of 6th 
week 
Treatment 60 18.57±2.24 14.72±2.26* 10.83±2.70*¨¨  8.18±3.36*¨¨  6.40±4.40* 
Short-term 42 18.58±2.24 14.67±2.22* 10.50±2.70*¨ 7.71±3.35*¨  5.93±4.33* 
Long-term 18 18.56±2.30 14.83±2.40* 11.61±2.59*¨ 9.28±3.21*¨   7.50±4.47*¨
Control 60 18.43±2.18 14.75±2.01* 12.38±2.55* 10.07±3.29*  7.85±4.76* 
Short-term 39 18.51±2.31 14.69±2.17* 11.92±2.65* 9.21±3.09*  6.49±4.51* 
Long-term 21 18.29±1.97 14.86±1.71* 13.20±2.18* 11.67±3.10* 10.38±4.22* 
Notes: The intragroup comparison, *P<0.01; the intergroup comparison, ¨P<0.05, and ¨¨P<0.01. 
Comparison of the Adverse Reactions 
At the end of the 6th week, the TESS score of the 
treatment group (0.40±0.72) was obviously lower 
than that of the control group (1.05±1.04), and the t
test showed a significant difference between the two 
groups (P<0.01). In the treatment group, 4 cases 
(6.7%) had profuse urination, 2 cases (3.3%) had dry 
mouth, and 1 case (1.7%) had sweating. These 
symptoms were mild and were not specially treated; 
no other symptoms were found in this group. In the 
control group, 5 cases (8.3%) had dizziness, 4 cases 
(6.7%) had asthenia, 4 cases (6.7%) had lethargy, 3 
cases (5.0%) had dry mouth, and 2 cases (3.3%) had 
cloudy vision. They were not specially treated, and 
no other adverse reactions were found in this group. 
The Ȥ2 tests for the adverse reactions showed 
significant differences between the two groups 
(P<0.01), suggesting that the adverse reactions of the 
XIA’s prescription are less and milder than those for 
estazolam.  
DISCUSSION 
According to the statistics by the WHO, the incidence 
of insomnia is 29% in developed countries. In 2003, 
an investigation made by the China Sleep Research 
Society revealed that the incidence of insomnia was 
38.2% among adults in China. Insomnia is a 
commonly-seen inorganic dyssomnia. It is a state of 
unsatisfied sleeping quality, which is characterized by 
difficulty in falling asleep, unsound sleep, ease in 
waking up, dreaminess, early awakening, inability to 
fall asleep after awakening, discomfort sensation 
after waking up, lassitude or sleepiness in the day 
time. Insomnia can give rise to headaches, dizziness, 
anxiety, mental depression, poor memory, and poor 
appetite, which directly affect the patient’s daily life 
and working ability. It has been proved by research 
that chronic insomnia can induce depression, and 
make young females have phenomena of senilism, 
such as grey-yellow complexion and increase of 
wrinkles; and can even decrease immunity of the 
human body, increase the incidence of cardiovascular 
and digestive diseases, and increase the risk of 
diabetes in males.4  
Presently, sleeping pills are still commonly used for 
insomnia, which, in addition to adverse reactions, can 
bring about drug resistance and dependence. And 
once the medication is dropped, 97% of the insomnia 
cases will have consistent insomnia again, leading to 
a vicious cycle. For this, based on TCM theory and 
the clinical experience of TCM physicians,5,6 and 
through the clinical practice, the authors have finally 
selected 14 Chinese drugs and made up a prescription 
for insomnia of the deficiency type. TCM holds that 
the location of insomnia is mainly in the heart, with 
the other zang organs involved. In clinical settings, 
the deficiency type is more frequently seen than the 
excess type. The XIA’s prescription is mainly 
indicated for insomnia with deficiency of both the 
heart and spleen, hyperactivity of fire due to yin
deficiency, incoordination between the heart and 
kidneys, stagnation of the liver-qi and deficiency of 
blood. It takes tranquilizing the mind as the basic 
treating principle by means of balancing qi, blood, 
yin, and yang of the zang-fu organs, nourishing the 
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heart and spleen, coordinating the heart and kidney, 
soothing the liver and nourishing blood, and 
supplementing qi to tranquilize the mind.  
The results of the present study have shown that the 
total effective rate of the XIA’s prescription was 
slightly higher than that of estazolam, but with no 
significant difference. However, the therapeutic 
effects of the former for long-term insomnia was 
obviously better than that of the latter. And the 
prescription does not bring about the adverse 
reactions as the commonly-used sedatives and 
hypnotics, such as dizziness, lethargy, dry mouth, and 
cloudy vision.  
This research proves that the XIA’s No.1 Sleeping 
Prescription can markedly shorten the time for falling 
asleep, decrease the frequency of night awakening, 
increase the total sleeping time, and improve the 
day-time mental state and physical functions. 
Moreover, it does not present  toxic side effects, and 
with no recurrence and abstinence reactions even 
after withdrawal of the drug. Therefore, it is 
suggested that the XIA’s prescription is a safe and 
effective drug for insomnia of the deficiency type, 
which is well accepted by patients.  
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